Trade Summary

2 days ago, Schoenberg Mark, serving as Chief Medical Officer at UroGen Pharma Ltd. (URGN), sold 5,222 shares at $27.30 per share, for a total transaction value of $142,560.60. Following this transaction, Schoenberg Mark now holds 139,763 shares of URGN.

This sale represents a 3.60% decrease in Schoenberg Mark's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Monday, June 8, 2026 and publicly disclosed via SEC Form 4 filing on Tuesday, June 9, 2026 at 1:59 PM ET, 1 day after the trade was made.

UroGen Pharma Ltd. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.